Want to see AGL full AI Analyst Report?
AGL Stock Chart & Stats
$98.00
-$2.27(-2.26%)
At close: 4:00 PM EDT
$98.00
-$2.27(-2.26%)
Day’s Range― - ―
52-Week Range$7.48 - $133.04
Previous CloseN/A
Volume247.62K
Average Volume (3M)322.23K
Market Cap
$1.55B
Enterprise Value-$137.79
Total Cash (Recent Filing)$231.41M
Total Debt (Recent Filing)$33.40M
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Aug 05, 2026EPS Estimate
0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.70
Shares Outstanding16,683,786
10 Day Avg. Volume342,073
30 Day Avg. Volume322,225
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)2.25
Price to Sales (P/S)0.05
P/FCF Ratio-2.40
Enterprise Value/Market Cap>-0.01
Enterprise Value/Revenue>-0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$64.38Price Target Upside-34.30% Downside
Rating ConsensusHold
Number of Analyst Covering15
EPS Forecast (FY)-3.04
Revenue Forecast (FY)$5.72B
Bulls Say, Bears Say
Bulls Say
Scaled Clinical ProgramsAgilon has operationalized clinical pathways at scale (CHF in ~90% of markets), which materially reduces avoidable inpatient use and improves guideline-directed care. That durable clinical infrastructure supports sustained cost avoidance, quality metrics, and stronger medical margins under value-based contracts.
Improved Risk-adjustment/data VisibilityBetter member-level data and a higher estimated risk-score lift improve revenue capture and predictability of capitation payments. This structural improvement enhances contract modeling, reduces surprise adjustments, and supports sustainable revenue and margin stability over the medium term.
Low Leverage On Balance SheetRelatively low debt reduces near-term refinancing and solvency risk, giving management flexibility to fund operations, clinical investments, or absorb cyclical losses. This balance-sheet breathing room is a durable defensive trait while the business scales and improves margins.
Bears Say
Persistent Negative Cash FlowOperating and free cash flow remain negative, meaning the core business consumes cash rather than funds itself. Even with some TTM improvement, persistent cash burn necessitates external financing or draw on equity, limiting capital for expansion and raising funding risk over the next several quarters.
Membership-driven Revenue DeclineMembership is the primary driver of capitation revenue; a 13% YoY MA drop materially reduces the revenue base and scale economics. Reduced attribution pressures medical-margin leverage and slows revenue recovery, constraining sustainable margin improvement and growth in the coming months.
Part D Reserving And Regulatory RiskPart D reserving timing and limited reconciliation data create revenue/expense volatility and reserve risk that can materially affect margins. Coupled with limited visibility into CMS's LEAD AI-inferred risk model, reimbursement and risk-score outcomes remain uncertain, threatening near-term predictability.
Agilon Health News
AGL FAQ
What was Agilon Health Inc’s price range in the past 12 months?
Agilon Health Inc lowest stock price was $7.48 and its highest was $133.04 in the past 12 months.
What is Agilon Health Inc’s market cap?
Agilon Health Inc’s market cap is $1.55B.
When is Agilon Health Inc’s upcoming earnings report date?
Agilon Health Inc’s upcoming earnings report date is Aug 05, 2026 which is in 5 days.
How were Agilon Health Inc’s earnings last quarter?
Agilon Health Inc released its earnings results on May 06, 2026. The company reported $2.94 earnings per share for the quarter, beating the consensus estimate of $1.041 by $1.899.
Is Agilon Health Inc overvalued?
According to Wall Street analysts Agilon Health Inc’s price is currently Overvalued.
Does Agilon Health Inc pay dividends?
Agilon Health Inc pays a Quarterly dividend of $0.45 which represents an annual dividend yield of N/A. See more information on Agilon Health Inc dividends here
What is Agilon Health Inc’s EPS estimate?
Agilon Health Inc’s EPS estimate is 0.11.
How many shares outstanding does Agilon Health Inc have?
Agilon Health Inc has 16,683,786 shares outstanding.
What happened to Agilon Health Inc’s price movement after its last earnings report?
Agilon Health Inc reported an EPS of $2.94 in its last earnings report, beating expectations of $1.041. Following the earnings report the stock price went up 117.81%.
Which hedge fund is a major shareholder of Agilon Health Inc?
Currently, no hedge funds are holding shares in AGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agilon Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$64.38 (-34.30% Downside)
$64.38 (-34.30% Downside)
Blogger Sentiment
Bullish
AGL Sentiment 70%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.14%
Trailing 12-Months
Company Description
Agilon Health Inc
Agilon Health, Inc. (AGL) is a healthcare services company focused on enabling community-based primary care physicians to manage and improve the health outcomes of senior (Medicare) patients under value-based care arrangements. The company partners with physician groups and supports them with operational infrastructure, clinical programs, technology and analytics, and payer contracting capabilities to help physicians succeed in models where reimbursement is tied to cost and quality performance rather than fee-for-service volume.
AGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed a balanced message: strong operational execution and meaningful near-term wins (data pipeline, risk adjustment upside, improved medical margin, scaled clinical programs and a sizable Q1 adjusted EBITDA beat) were tempered by structural challenges — notably a sizable year-over-year MA membership decline, a YoY revenue decline, Part D reserving uncertainty, cautious early-year cost recording, and conservative full-year adjusted EBITDA guidance. Management emphasized disciplined, sustainable growth and quality-driven improvements rather than aggressive expansion, resulting in positive operational momentum but continued near-term prudence and uncertainty.View all AGL earnings summariesAGL Stock 12 Month Forecast
Average Price Target
$64.38
▼(-34.30% Downside)
Technical Analysis
AMN Healthcare Services
―
Cross Country Healthcare
―
InnovAge Holding
―
P3 Health Partners
―
biote
―
Ownership Overview
5.67% Insiders
16.61% Mutual Funds
24.33% Other Institutional Investors
43.17% Public Companies and
Individual Investors